Skip to main content

Table 1 Comparison of prevalence of part of obesity-associated complications between PWS patients and controls

From: Do patients with Prader–Willi syndrome have favorable glucose metabolism?

References

PWS patients

Obese controls

N

Mean age (years)

T2DM/IGT (%)

Other (%)

N

Mean age (years)

T2DM/IGT (%)

Other (%)

Greenswag [142]

232

23

T2DM (19%)

     

Tauber et al. [143]

28

 

T2DM (7%)

     

Butler et al. [144]

108

18.7

T2DM (14%)

     

Krochik et al. [11]

75

8.4

T2DM (0%)

 

395

10.7

T2DM (1.5%)

 

Thomson et al. [145]

30

 

T2DM (13.3%)

     

Sinnema et al. [146]

102

 

T2DM (17%)

     

Sinnema et al. [147]

12

57.8

T2DM (50%)

     

Grugni et al. [4]

87

26 (P50)

 

MS (41.4%)

85

28 (P50)

 

MS (45.9%)

Bedogni et al. [18]

20

30

 

NAFLD (25%)

27

33

 

NAFLD (59%)

Fintini et al. [10]

21

12.4

IGT (14.3%)

 

42

12.5

IGT (21.4%)

 

Fintini et al. [5]

274

20.3

T2DM (13.5%), IGT (10.2%)

     

Yang et al. [17]

211

 

T2DM (13.7%)

     

Damen et al. [148]

43

 

T2DM (5.1%)

     
  1. T2DM type 2 diabetes mellitus, IGT impaired glucose tolerance, MS metabolic syndrome, NAFLD non-alcoholic fatty liver disease